ESTHER
CHAMORRO DE VEGA
Profesora asociada de Ciencias de la Salud
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublications in collaboration with researchers from Instituto de Investigación Sanitaria Gregorio Marañón (21)
2023
-
Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS
Journal of medical economics, Vol. 26, Núm. 1, pp. 463-472
-
Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
Open Forum Infectious Diseases, Vol. 10, Núm. 2
-
Remdesivir and SARS-CoV-2 monoclonal antibodies to prevent COVID-19 progression in hematological patients: an observational study
Pharmacological Reports, Vol. 75, Núm. 5, pp. 1254-1264
2022
-
Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
Revista Espanola de Quimioterapia, Vol. 35, Núm. 3, pp. 279-283
-
Design and implementation of a mobile app for the pharmacotherapeutic follow-up of patients diagnosed with immune-mediated inflammatory diseases: eMidCare
Frontiers in Immunology, Vol. 13
-
Dolutegravir-Based Dual Therapies in HIV Pretreated Patients: A Real-Life Study in Madrid
Annals of Pharmacotherapy, Vol. 56, Núm. 4, pp. 401-411
-
Evaluation of the hospital care quality perceived by patients with immune-mediated inflammatory diseases from the pharmacy service. SACVINFA study
Journal of Clinical Pharmacy and Therapeutics, Vol. 47, Núm. 12, pp. 2020-2029
-
Information and Communication Technologies in Patients With Immune-Mediated Inflammatory Diseases: Cross-sectional Survey
Journal of medical Internet research, Vol. 24, Núm. 9, pp. e37445
-
The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search
Journal of Medical Internet Research, Vol. 24, Núm. 3
2021
-
COVID-19 in hospitalised patients in Spain: a cohort study in Madrid
International Journal of Antimicrobial Agents, Vol. 57, Núm. 2
-
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain
Expert Review of Clinical Pharmacology, Vol. 14, Núm. 2, pp. 249-260
2020
-
Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients
Annals of Pharmacotherapy, Vol. 54, Núm. 7, pp. 633-643
-
Etiology and Prognosis of Pneumonia in Patients with Solid Tumors: A Prospective Cohort of Hospitalized Cases
Oncologist, Vol. 25, Núm. 5, pp. e861-e869
-
Topical Administration of Amphotericin B as an Effective Adjuvant Treatment for a Deep Fungal Infection of Diabetic Foot Injury
American journal of therapeutics, Vol. 27, Núm. 6, pp. e670-e671
2019
-
A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and pseudomonas aeruginosa infection
Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 2
2018
-
Effectiveness, Safety, and Costs of a Treatment Switch to Dolutegravir Plus Rilpivirine Dual Therapy in Treatment-Experienced HIV Patients
Annals of Pharmacotherapy, Vol. 52, Núm. 1, pp. 11-18
-
Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports
Medicina Clinica
-
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study
Expert Opinion on Drug Safety, Vol. 17, Núm. 3, pp. 235-241
2017
-
Improving pharmacotherapy outcomes in patients with hepatitis C virus infection treated with direct-acting antivirals: The GRUviC project
International Journal of Clinical Practice, Vol. 71, Núm. 8
-
Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks
International Journal of Clinical Practice, Vol. 71, Núm. 8